Effect and Safety of Recombinant Human Interferon α-2b Spray on Herpangina in Pediatric Patients

Fecha de inicio: 1 de junio de 2016

Inclusion Criteria: Subjects should meet all of the following: 1. meet the diagnostic criteria for pediatric herpangina; 2. ages 1-7 years, no limitation for gender; 3. within 72 hours of onset; 4. the main organs (heart, liver, kidney and lung) function normally; 5. follow up according to requirements and be hospitalized for observation; 6. the guardian is fully informed and signed informed consent. Exclusion Criteria: Subjects should be excluded if meet any of the following: 1. have allergy history of interferon; 2. heart failure, respiratory insufficiency,liver and kidney dysfunction or severe malnutrition and other serious disease, or immunodeficient; 3. children with epilepsy or other neurological disorders; 4. other pathogens exist at the same time; 5. the researchers believe that it is not appropriate to participate in this study.